Neuphoria Therapeutics Announces Merger Agreement with Scancell

What Happened

• Neuphoria Therapeutics Inc. (NEUP) and Scancell Holdings plc signed an Agreement and Plan of Merger dated July 23, 2026 (reported on Form 8‑K filed July 24, 2026). Under the agreement, Scancell Merger Sub, Inc. will merge into Neuphoria and Neuphoria will become an indirect wholly owned subsidiary of Scancell. At the Effective Time each outstanding Neuphoria common share (other than excluded shares) will convert into (i) a number of Scancell American Depositary Shares (Parent ADSs) per the Exchange Ratio and (ii) one contingent value right (CVR).
• The Exchange Ratio and illustrative ownership were calculated on a pro forma basis using assumed values (Parent Valuation $144,612,002; Company Valuation $24,598,949). Using an assumed PIPE financing of $38.6 million, pre‑Merger Neuphoria holders are projected to own ~11.1% of the combined company (fully diluted), pre‑Merger Scancell shareholders ~64.9%, and PIPE subscribers ~17.3%. The Merger Agreement is subject to customary closing conditions, regulatory and stockholder approvals, Nasdaq listing approval, effectiveness of a Form F‑4, and financing requirements described below.

Key Details

• Date/filing: Merger Agreement dated July 23, 2026; Form 8‑K filed July 24, 2026.
• Consideration: Parent ADSs (per Exchange Ratio) plus one CVR per Neuphoria share; CVRs give a pro rata right to 100% of certain net proceeds received by Parent/affiliates from specified partner agreements and monetizations (including the Merck collaboration and other licence agreements) for up to 15 years. CVRs are non‑transferable in most cases, carry no voting rights, and may yield no payment.
• Financing & conditions: Scancell entered PIPE Subscription Agreements and is pursuing a UK institutional placing (~$12M) and retail offer (up to ~$3M). Closing conditions include receipt of not less than $75.0 million in gross cash proceeds from the concurrent financing (a stated condition), Nasdaq listing approval, Form F‑4 effectiveness, Parent and Company shareholder approvals, and minimum Closing Net Cash of $10.0M as of Dec 31, 2026 or at Closing. The Merger must close by Feb 28, 2027 (subject to limited extension).
• Governance & protections: Certain directors, officers and major holders of both companies have signed voting/support and lock‑up agreements to vote in favor of the transactions. A letter with Armistice modifies a warrant payoff: if the Black‑Scholes cash‑out value exceeds $3.5M, the excess can be paid in Scancell shares/ADSs (with a 125% multiplier on share calculation).

Why It Matters

• This transaction would take Neuphoria private as an indirect Scancell subsidiary and replaces Neuphoria common stock with Scancell ADSs plus CVRs tied to future partner payments — changing liquidity, ownership percentage, and upside exposure for existing shareholders.
• The deal is conditioned on substantial financing and regulatory approvals (including at least $75M in concurrent financing and Nasdaq listing), so completion is not guaranteed. CVRs offer potential future payments only if specific partner revenues/monetizations occur, and they carry transfer restrictions and no voting rights.
• Insiders have committed to vote for the merger, which may increase the likelihood shareholders approve the deal if financing and other conditions are met. Investors should watch filings on the Form F‑4, shareholder meeting materials, and updates about the concurrent financing and Nasdaq listing.